MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 922 products for "MAPK".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
R18
CAS:14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.Formula:C101H157N27O29S3Purity:98%Color and Shape:SolidMolecular weight:2309.69TAT-PAK18 R192A
TAT-PAK18 R192A is an inactive Tat-Pak peptide. It does not influence Rac1 translocation triggered by any tested proteins.Formula:C143H247N55O37Molecular weight:3326.91369FAM49B (190-198) mouse
CAS:FAM49B (190-198) mouse represents a peptide fragment of the mitochondria-localized protein FAM49B, which is instrumental in regulating mitochondrial fission, function, and integrity, in addition to influencing tumor progression. Beyond its role in mitochondrial dynamics, FAM49B serves as a negative regulator of T cell activation by inhibiting GTPase Rac activity and affecting cytoskeleton reorganization.Formula:C49H71N9O14SColor and Shape:SolidMolecular weight:1042.2BI1701963
BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.Formula:C47H62N8O4SColor and Shape:SolidMolecular weight:835.11Mitogen-activated protein kinase 1
CAS:Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.Purity:98%Color and Shape:SolidKRAS G12C inhibitor 18
CAS:KRAS G12C inhibitor 18 is a potent, orally active compound that inhibits KRAS G12C and exhibits anti-tumor activities.Formula:C25H20ClFN4O3SColor and Shape:SolidMolecular weight:510.97LYMTAC-2
LYMTAC-2 is a lysosome-targeting chimera (LYMTAC) developed to degrade membrane-associated proteins through lysosomal membrane proteins (LMP) such as RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with target proteins like KRASG12D, facilitating their relocation to lysosomes and resulting in ubiquitin-dependent degradation. This compound has potential for studying membrane protein regulation and devising strategies to counter resistance in KRAS-driven signaling pathways.Color and Shape:SolidMolecular weight:1248.44SHP2-IN-38
SHP2-IN-38 is an innovative green fluorescent inhibitor targeting SHP2, exhibiting IC50 values as follows: 2.89 μM (SHP2), 8.73 μM (SHP1), 11.08 μM (PTP1B), and 33.07 μM (TCPTP). It impedes the SHP2-mediated ERK signaling pathway and inhibits MV4-11 cell proliferation in vitro with an IC50 of 7.90 μM. The excitation wavelength of SHP2-IN-38 is 360 nm, with a maximum emission wavelength of 550 nm in DMSO and 540 nm in DMF. Additionally, it demonstrates green fluorescent imaging in HeLa cells and zebrafish.Color and Shape:Odour SolidPROTAC ERK5 degrader-1
CAS:PROTACERK5 degrader-1 (compound 2) is a bifunctional ERK5 PROTAC degrader. It induces the degradation of ERK5 in MOLT-4 cells via a VHL-mediated proteasome pathway. PROTACERK5 degrader-1 is useful for studying diseases or disorders characterized by abnormal ERK5 activity.Formula:C54H67F3N10O6SColor and Shape:SolidMolecular weight:1041.23HRS 4642
CAS:HRS 4642 is a selective KRAS G12D inhibitor with a Kd value of 0.083 nM, antitumour, inhibits phosphorylation of downstream MEK and ERK proteins.Formula:C34H35F3N6O3Purity:99.17%Molecular weight:632.68SMU-L11
SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM) that recruits the MyD88 adaptor protein, activating downstream NF-κB and MAPK signaling pathways. In mouse models, SMU-L11 significantly enhances immune cell activation and boosts CD4+ T and CD8+ T cell proliferation, leading to direct tumor cell destruction and inhibition of tumor growth. This compound has applications in cancer research and potential in studying immune system disorders.Formula:C19H24N4OMolecular weight:324.19501JTP10-△-TATi TFA
JTP10-△-TATi TFA is a selective inhibitor of JNK2 peptide (IC50: 92 nM), exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.Formula:C120H213F3N48O28Purity:98%Color and Shape:SolidMolecular weight:2833.28PPARγ agonist-21
PPARγagonist-21 (Compound 9a) is a PPARγ agonist with an EC50 of 3.12 μM. It inhibits NF-κB by activating PPAR-γ and reduces the assembly of the NLRP3 inflammasome. PPARγagonist-21 blocks interactions between NLRP3-ASC and NLRP3-NEK7, alleviating the severity of gouty arthritis.(RS)-G12Di-1
(RS)-G12Di-1 is a selective covalent inhibitor of K-Ras-G12D.Formula:C37H35FN6O4Color and Shape:SolidMolecular weight:646.27038SOS1-IN-24
SOS1-IN-24 (Compound 15) is an SOS1 inhibitor with an IC50 of 0.398 μM, effectively blocking the interaction of SOS1::KRAS12D. It is applicable in research on cancers such as pancreatic and colorectal cancer.MEK/RAF-IN-1
MEK/RAF-IN-1 (Compound 16b) serves as an inhibitor targeting both MEK and RAF, demonstrating potent efficacy with IC 50 values reported at 28 nM for MEK1, and 3 nM for both BRAF and BRAFV600E. This compound exhibits significant antitumor capabilities, effectively curbing cell proliferation in vitro in MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Furthermore, MEK/RAF-IN-1 significantly restricts tumor growth in xenograft mouse models employed in the study of colorectal cancer.Formula:C28H29F3N6O5SColor and Shape:SolidMolecular weight:618.63BChE/p38-α MAPK-IN-2
BChE/p38-α MAPK-IN-2 is a dual inhibitor of BChE and p38-α MAPK. It has an IC50 of 5.1 nM for hBChE and exhibits a 1000-fold selectivity over hAChE. Its IC50 for p38α MAPK is 8.12 μM. BChE/p38-α MAPK-IN-2 demonstrates neuroprotective properties, making it useful for research on neurological disorders such as Alzheimer's disease.CST905
CAS:CST905 is an efficient PROTAC BRAF-V600E degrader with a DC50 of 18 nM, suitable for cancer research.Formula:C51H58F2N10O7S2Molecular weight:1025.20ASP6918
ASP6918 is a potent, orally active KRAS G12C inhibitor with an IC50 of 0.028 µM. It inhibits cell growth and demonstrates antitumor activity.Formula:C36H43N7O3Color and Shape:SolidMolecular weight:621.34274MS243
MS243 is a potent KRASG12D PROTAC degrader with a DC50 of 4.2 nM. It enhances the proximity of KRASG12D to the VHL E3 ubiquitin ligase, facilitating ubiquitination and proteasomal degradation of KRASG12D, thereby inhibiting the proliferation of cancer cells harboring KRASG12D. MS243 is applicable to research on KRASG12D-bearing cancers, such as colon cancer and pancreatic cancer.
